EZH2 and follicular lymphoma: Tazemetostat is the most advanced EZH2 inhibitor and was granted accelerated approval for adults with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation (Fig. 4; Italiano et al. 2018).